Reshaping the HIV treatment and prevention landscape

Improved sales force effectiveness across key markets Nucala (US) 23% 20% 18% Q4 2017 Q4 2018 % of calls with Good Selling Outcome .... STEM Industry Average STEM Industry Top Quartile Nucala (Germany) 13% 24% 32% Nucala (Japan) 17% 25% 41% gsk Q3 2019 Q1 2018 Q1 2019 Q3 2019 Q3 2017 Q3 2018 Q4 2019 Source: STEM audits (STEM is an industry leading independent 3rd party, specialising in strategic benchmarking of internal strategic and operational alignment of cross functional commercial and medical teams, quality of execution and outcomes) Good Selling Outcome: interaction where customer behaviour change has been agreed 30

View entire presentation